Literature DB >> 19118228

Long-term macrolide therapy in chronic inflammatory airway diseases.

P A J Crosbie1, M A Woodhead.   

Abstract

In addition to direct antibacterial actions, 14- and 15-member-ring macrolides have immune modulating effects that appear to be the reason for clinical benefit in diffuse panbronchiolitis. A literature search was conducted for studies of the clinical effectiveness of macrolides in other chronic lung conditions. A number of studies were identified that showed short-term beneficial outcomes or the potential for such outcomes in cystic fibrosis, bronchiectasis, chronic obstructive pulmonary disease, asthma and post-transplant obliterative bronchiolitis. The studies were limited by small patient numbers, different outcome measures and short-term follow-up, and were not designed to assess potentially harmful effects. Further large prospective and long-term studies are required in order to identify potential benefit and harm before these agents can be recommended routinely for these conditions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19118228     DOI: 10.1183/09031936.00042208

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  30 in total

Review 1.  Update in asthma 2009.

Authors:  Wendy C Moore; Rodolfo M Pascual
Journal:  Am J Respir Crit Care Med       Date:  2010-06-01       Impact factor: 21.405

2.  Diffuse panbronchiolitis in a 67-year-old Chinese man.

Authors:  Kristof De Smet; Michel De Maeseneer; Bart Ilsen; Johan De Mey
Journal:  Emerg Radiol       Date:  2010-10-24

3.  Evaluation and management of pulmonary disease in ataxia-telangiectasia.

Authors:  Sharon A McGrath-Morrow; W Adam Gower; Cynthia Rothblum-Oviatt; Alan S Brody; Claire Langston; Leland L Fan; Maureen A Lefton-Greif; Thomas O Crawford; Michelle Troche; John T Sandlund; Paul G Auwaerter; Blaine Easley; Gerald M Loughlin; John L Carroll; Howard M Lederman
Journal:  Pediatr Pulmonol       Date:  2010-09

Review 4.  Interventions for bronchiectasis: an overview of Cochrane systematic reviews.

Authors:  Emma J Welsh; David J Evans; Stephen J Fowler; Sally Spencer
Journal:  Cochrane Database Syst Rev       Date:  2015-07-14

5.  Azithromycin distinctively modulates classical activation of human monocytes in vitro.

Authors:  M Vrančić; M Banjanac; K Nujić; M Bosnar; T Murati; V Munić; D Stupin Polančec; D Belamarić; M J Parnham; V Eraković Haber
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

6.  Relation between chronic obstructive pulmonary disease and antibiotics.

Authors:  Salvador Sialer; Liapikou Adamantia; Mónica Guerrero; Antoni Torres
Journal:  Curr Infect Dis Rep       Date:  2012-06       Impact factor: 3.725

Review 7.  Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases.

Authors:  P Zarogoulidis; N Papanas; I Kioumis; E Chatzaki; E Maltezos; K Zarogoulidis
Journal:  Eur J Clin Pharmacol       Date:  2011-11-22       Impact factor: 2.953

8.  A genome-wide analysis of targets of macrolide antibiotics in mammalian cells.

Authors:  Amita Gupta; Aye Ökesli-Armlovich; David Morgens; Michael C Bassik; Chaitan Khosla
Journal:  J Biol Chem       Date:  2020-01-08       Impact factor: 5.157

9.  A novel macrolide/fluoroketolide, solithromycin (CEM-101), reverses corticosteroid insensitivity via phosphoinositide 3-kinase pathway inhibition.

Authors:  Y Kobayashi; H Wada; C Rossios; D Takagi; C Charron; P J Barnes; K Ito
Journal:  Br J Pharmacol       Date:  2013-07       Impact factor: 8.739

10.  Sex effects in the association between airway microbiome and asthma.

Authors:  Renjin Chen; Leran Wang; Tammy Koch; Vanessa Curtis; Huiqing Yin-DeClue; Scott A Handley; Liang Shan; Michael J Holtzman; Mario Castro; Leyao Wang
Journal:  Ann Allergy Asthma Immunol       Date:  2020-09-12       Impact factor: 6.347

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.